Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. The Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update' provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The data and analysis within this report are driven by the Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
The Dry Powder Inhaler Devices report provides key information and data related to:
- Extensive coverage of the Dry Powder Inhaler Devices under development
- Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates
- Reviews of major players involved in the pipeline product development.
- Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and the number of trials of the major Dry Powder Inhaler Devices pipeline products.
- Review of Recent Developments in the segment/industry
The Dry Powder Inhaler Devices report enables you to:
- Access significant competitor information, analysis, and insights to improve your R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Formulate market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
The Publisher's Differentiation
This report is prepared using data sourced from in-house databases, secondary and primary research by the team of industry experts.The data and analysis within this report are driven by the Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
- 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
- 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
- 64,000+ medical equipment company profiles
- 5,600+ company profiles of medical equipment manufacturers in China and India
- 2,200+ company profiles of medical equipment manufacturers in Japan
- 1,200+ companies’ revenue splits and market shares
- 1,600+ quarterly and annual medical equipment company financials
- 850+ medical equipment company SWOTs
- 28,000+ pipeline product profiles
- 56,400+ marketed product profiles
- 47,000+ clinical trials
- 41,500+ trial investigators
- 7,000+ reports on companies with products in development
- 44,000+ deals in the medical equipment industry
- 1,100+ surgical and diagnostic procedures by therapy area
- 50+ key healthcare indicators by country
- 431,000+ Themes Content Items
- 600+ Influencers
- 1,900+ Analysts & Researchers
- 0.5m+ Community Members
- 141,000+ Macroeconomic Indicators
- 1,013,000+ City Indicators
Scope
- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry
Reasons to Buy
The report enables you to -- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
5 Dry Powder Inhaler Devices Companies and Product Overview
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acorda Therapeutics Inc
- Advent Pharmaceuticals Pty Ltd
- Aespira Ltd.
- AKELA Pharma Inc. (Inactive)
- Bayer AG
- Cambridge Healthcare Innovations Ltd
- Creare LLC
- DMK Pharmaceuticals Corp
- Eli Lilly and Co
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Hovione Technology Ltd
- Iconovo AB
- Lupin Pharmaceuticals Inc
- MannKind Corp
- Monash University
- Nektar Therapeutics
- Ology Bioservices Inc
- OPKO Health Inc
- OtiTopic Inc
- Phargentis SA
- Pharmaxis Ltd
- PureIMS BV
- Quench Medical Inc
- Respira Therapeutics Inc
- Respirent Pharmaceuticals Co Ltd
- Sandoz International GmbH
- Sheffield Hallam University
- Shin Nippon Biomedical Laboratories Ltd
- Spyryx Biosciences Inc (Inactive)
- Teva Pharmaceutical Industries Ltd
- Transpire Bio Inc
- University of Kansas
- University of Sydney
- University of Texas Medical Branch at Galveston
- Vectura Group Plc
- Verona Pharma Plc
- Virginia Commonwealth University
